Agenus (NASDAQ:AGEN) Given “Neutral” Rating at HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Separately, Robert W. Baird lowered their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.75.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $1.78 on Tuesday. Agenus has a 1 year low of $1.65 and a 1 year high of $19.69. The company has a market capitalization of $41.76 million, a PE ratio of -0.16 and a beta of 1.23. The business has a fifty day moving average price of $3.14 and a two-hundred day moving average price of $3.75.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. Sell-side analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC grew its position in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 27,309 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Agenus by 2,271.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 37,866 shares during the period. Walleye Capital LLC purchased a new position in Agenus during the 3rd quarter valued at about $1,003,000. HighTower Advisors LLC increased its position in shares of Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the period. Finally, Point72 DIFC Ltd lifted its holdings in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.